Substance-use treatment software has to handle three things a general behavioral health EHR usually does not. It needs to support level-of-care determination against ASAM criteria, since placement decisions and the documentation justifying them drive both clinical workflow and payer authorization. It has to implement 42 CFR Part 2 consent and segmentation, because SUD records carry confidentiality protections stricter than HIPAA and cannot simply flow into general integrations. And it needs to document group therapy properly, which breaks the one-patient-one-note assumption most EHRs are built on — a single session generates a note per participant, sharing group content while keeping individual observations separate and individually protected. A product that handles individual outpatient mental health well can fail badly on that third requirement alone, so it is worth testing before anything else.

What Makes SUD Software Different?

Substance-use treatment sits at the intersection of three requirements no general behavioral health product has to solve together: a structured clinical assessment framework driving placement and payer authorization, a stricter-than-HIPAA confidentiality regime, and a group-based treatment model most EHR data structures were never designed for. Any one of the three is a real requirement on its own; together they’re what actually separates SUD-specific software from a general mental health EMR configured to look like it fits.

ASAM Criteria and Level of Care

The ASAM Criteria’s current edition (the Fourth Edition, released October 2023) assesses patients across six dimensions to determine level-of-care placement — a real, structured framework, not a subjective clinical judgment call. The current continuum spans Levels 1 through 4, including a long-term remission monitoring level and co-occurring-enhanced variants (1.5 COE through 4 Psychiatric) for patients with both SUD and psychiatric needs. Software has to support this assessment, the resulting placement decision, and periodic reassessment as documented, structured data — because payer authorization and continued-stay justification both depend on it being reconstructable, not just clinically remembered.

42 CFR Part 2 in Practice

Briefly here, since I go through the full regulatory and technical requirement in the dedicated Part 2 post — the short version for SUD-specific software: consent has to be captured as enforceable data naming recipient and purpose, redisclosure has to be restricted and notice-tagged, and the software has to be able to reconstruct exactly what was disclosed under which consent. That’s not optional infrastructure for a genuine SUD treatment program — it’s close to the core of what the software exists to get right.

Group Therapy Documentation

This is the specific, checkable detail most comparisons miss entirely. Individual outpatient therapy is one-patient-one-note, and most EHR data models are built around that assumption. SUD treatment runs heavily on group sessions, and a single group session generates documentation for every participant — shared content about what the group covered, plus individual, protected observations specific to each patient. Software that can’t structurally separate the shared group content from each patient’s individual, confidential notes within the same session forces staff into workarounds — copying shared content into every individual note by hand, or worse, documenting group sessions as though they were individual ones and losing the group structure entirely. Test this specific workflow directly during evaluation; it’s rarely obvious from a demo built around individual sessions.

Opioid Treatment Program Requirements

Where applicable — for an opioid treatment program specifically, not every SUD program — federal requirements under SAMHSA’s Federal Guidelines for Opioid Treatment Programs, updated in 2024, govern medication dosing and dispensing documentation, take-home dose determinations (up to 28 days for patients stable in treatment, up to 14 for those who may benefit from more structured monitoring), and the accreditation reporting an OTP has to maintain. Verify current federal and any state-specific take-home requirements directly, since dosing flexibility policy has shifted in recent years and continues to evolve. If your software serves an OTP specifically, this is a distinct requirement set on top of everything else in this post, not a variant of general SUD documentation.

Outcome Measurement and Reporting

Real operational reality for SUD programs: much of this software’s reporting exists to satisfy state block-grant funding requirements and payer authorization, not just internal quality tracking. Confirm during evaluation that the specific reports your program actually needs to produce for its funding sources are genuinely supported, not theoretically configurable.

What the Platforms Do Well

Streamline Healthcare, BestNotes and Qualifacts each have a real, specific presence in this category, and fair, non-promotional framing is worth taking seriously here — we don’t sell a competing product, which is exactly the position that lets an honest comparison exist in a category otherwise dominated by vendor-published content.

Next Steps

If you’re evaluating SUD treatment software, test the group-therapy documentation workflow directly before anything else — it’s the single detail most likely to reveal whether a platform was actually built for this specialty or adapted from a general behavioral health product. For the full Part 2 requirement, see our dedicated post. Talk to our team if you’re building or extending software for this space.